Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, both GRN and TMEM106B have already been associated with neuropathological features of AD46–48.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058 · cited 1×
“Initial papers observed features of PGRN immunoreactivity in microglia around senile plaques in AD cases when comparison was being made with neuropathological features of FTLD due to GRN mutations [13,127].”
ResultElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundTang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761 · cited 2×
“It had been speculated that if PGRN could function by blocking TNF-α activation, it would provide a rationale for the use of PGRN in diseases involving excess TNF-α including RA [95].”
BackgroundLui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729 · cited 7×
“Increased numbers of activated microglia and C1qa immunoreactivity were also observed in human FTLD GRN mutation carriers but not in AD cases [10].”
BackgroundResultInfluentialSpangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Conversion of Proepithelin to Epithelins
Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Wright, C. D., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01141-8 · Cited by 633 · cited 1×
“PGRN cleavage is prevented by secretory leukocyte protease inhibitor (SLPI), which binds directly to PGRN linker sequences [49].”
Background
Cited by
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Advancing cell therapy for neurodegenerative diseases
Temple, S. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.03.017 · Cited by 198
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Cell type-specific inference of differential expression in spatial transcriptomics
Cable, D. M., Murray, E., Shanmugam, V., Zhang, S., Zou, L. S., Diao, M., Chen, H., Macosko, E. Z., Irizarry, R. A., & Chen, F. (2022) · Nature Methods · doi:10.1038/s41592-022-01575-3 · Cited by 164
“…anti-inflammatory gene Grn was upregulated in microglia near plaque (log 2 fold-change 0.79, P = 6 × 10 − 4 ), consistent with previous knowledge 40 . progenitors create radial projections out from the hypothalamic midline, which are used as scaffolds for the migration of differentiating…”
BackgroundResultInfluentialCano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“Progranulin, a glycoprotein mainly secreted by activated microglia, is involved in the modulation of neuroinflammation [73].”
BackgroundWang, C., Zhang, L., Ndong, J. D. L. C., Hettinghouse, A., Sun, G., Chen, C., Zhang, C., Liu, R., & Liu, C.-J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1630-1 · Cited by 107
“Meanwhile, the polymorphism of Grn gene is associated with the lateonset Alzheimer’s disease [31] and exogenous addition of PGRN can protect against amyloid beta deposition and toxicity in an Alzheimer’s animal model [32, 33].”
BackgroundGenomics of Alzheimer’s disease implicates the innate and adaptive immune systems
Li, Y., Laws, S. M., Miles, L. A., Wiley, J. S., Huang, X., Masters, C. L., & Gu, B. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03986-5 · Cited by 111
Proteomic changes upon treatment with semaglutide in individuals with obesity
Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03355-2 · Cited by 86
Role of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction
Bandyopadhyay, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653334 · Cited by 61
“Increased C1q andC3 stimulate phagocytosis and altermicroglial reactivity, which causes synaptic and cognitive loss in AD (Mendsaikhan et al., 2019).”
BackgroundSecreted Chaperones in Neurodegeneration
Chaplot, K., Jarvela, T. S., & Lindberg, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00268 · Cited by 66
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
Dhauria, M., Mondal, R., Deb, S., Shome, G., Chowdhury, D., Sarkar, S., & Benito‐León, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010911 · Cited by 70
“Studies have revealed that increased levels of the progranulin-expressing gene are found in the blood of MCI and AD patients [150,151].”
BackgroundThe Role of Glial Cell Senescence in Alzheimer's Disease
Alshaebi, F., Sciortino, A., & Kayed, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70051 · Cited by 60
“Several ad risk factors, such as APOE, TREM2, PGRN, and NLRP3, are specifically associated with glial cells and are responsible for the altered phagocytosis of Aβ and the instauration of a pro-inflammatory state (Raulin et al. 2022; Mendsaikhan et al. 2019; Li et al. 2023; Heneka et al. 2013).”
Gaucher disease: Basic and translational science needs for more complete therapy and management
Grabowski, G. A., Antommaria, A. H. M., Kolodny, E. H., & Mistry, P. K. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.12.291 · Cited by 64
Haddad, M., Perrotte, M., Khedher, M. R. B., Demongin, C., Page, A. Y. L., Fülöp, T., & Ramassamy, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194906 · Cited by 44
Progranulin in neurodegenerative dementia
Wang, X., Zeng, P. H., Fang, Y., Zhang, T., & Tian, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15378 · Cited by 40
“In the extracellular space, several proteases including neutrophil elastase (NE), matrix metalloproteinase 9 (MMP9), MMP12, MMP14, and a disintegrin and metalloproteinase with thrombospondin 7 (ADAMTS7) cleave PGRN into GRNs (Mendsaikhan et al., 2019).”
BackgroundInfluentialAnti-sortilin1 Antibody Up-Regulates Progranulin via Sortilin1 Down-Regulation
Miyakawa, S., Sakuma, H., Warude, D., Asanuma, S., Arimura, N., Yoshihara, T., Tavares, D., Hata, A., Ida, K., Hori, Y., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586107 · Cited by 39
“PGRN is a widely distributed pleiotropic protein that consists of seven and half cysteine-rich repeats (Mendsaikhan et al., 2019).”
BackgroundYao, Y., Li, R., Guo, Y.-J., Zhao, Y. X., Guo, J., Ai, Q., Zhong, L., & Lü, D. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08671-1 · Cited by 35
Gillett, D. A., Wallings, R. L., Huarte, O. U., & Tansey, M. G. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02965-w · Cited by 34
“In the middle temporal gyrus, the size and number of PGRN-associated plaques increased in AD samples, and PGRN expression colocalized with microglia (IBA1 + cells) and vasculature (CD31 + cells) but not with astrocytes (GFAP + cells) [176].”
BackgroundTakahashi, H., Bhagwagar, S. Z., Nies, S. H., Ye, H., Han, X., Chiasseu, M., Wang, G., Mackenzie, I. R., & Strittmatter, S. M. (2024) · Nature Communications · doi:10.1038/s41467-024-45692-3 · Cited by 32
Suggesting 7,8-dihydroxyflavone as a promising nutraceutical against CNS disorders
Paul, R. K., Nath, J., Paul, S., Mazumder, M. K., Phukan, B. C., Roy, R., Bhattacharya, P., & Borah, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105068 · Cited by 32
Alzheimer’s Disease Research Using Human Microglia
Lue, L., Beach, T. G., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8080838 · Cited by 32
Self-citationProgranulin mutations in clinical and neuropathological Alzheimer's disease
Vardarajan, B. N., Reyes‐Dumeyer, D., Piriz, A. L., Lantigua, R., Medrano, M. Z., Rivera, D., Jiménez‐Velázquez, I. Z., Martin, E. R., Pericak‐Vance, M. A., Bush, W. S., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12567 · Cited by 27
“diffuse plaque burden; (4) neuritic plaque burden; (5) hyperphospho-”
BackgroundQureshi, Y. H., Baez, P., & Reitz, C. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00262-20 · Cited by 25
“that mutations in PGRN modulate lysosomal activity in both of these cell types, which in turn leads to AD pathology (122, 123).”
BackgroundZhao, X., Lin, Y., Liou, B., Fu, W., Jian, J., Fannin, V., Zhang, W., Setchell, K. D. R., Grabowski, G. A., Sun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210442120 · Cited by 26
Wittrahm, R., Takalo, M., Kuulasmaa, T., Mäkinen, P. M., Mäkinen, P., Končarević, S., Fartzdinov, V., Selzer, S., Kokkola, T., Antikainen, L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106140 · Cited by 22
“Progranulin (GRN) expression is increased in activated microglia and higher progranulin levels in CSF have been associated with advanced stages of AD (68,69).”
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets
Ahremenko, E. A., Andreev, A., Apushkin, D., & Korkotian, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411995 · Cited by 23
“Progranulin deficiency causes neuronal ceroid lipofuscinosis—characterized by pathological accumulation of toxic lipo-fuscin pigments that impair lysosomal function—and frontotemporal dementia, and is associated with an increased risk of AD and other neurodegenerative diseases [133,134].”
A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses
Du, H., Wong, M. Y., Zhang, T., Santos, M. N., Hsu, C., Zhang, J., Yu, H., Luo, W., & Hu, F. (2021) · Life Science Alliance · doi:10.26508/lsa.202000874 · Cited by 21
“In Alzheimer’s disease (AD) mouse models and human patients, PGRN was found to be highly expressed in the microglia surrounding Aβ plaques (Minami et al., 2014) (Mendsaikhan et al., 2019; Pereson et al., 2009).”
BackgroundProgranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease
Zhao, X., Liberti, R., Jian, J., Fu, W., Hettinghouse, A., Sun, Y., & Liu, C.-J. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02127-6 · Cited by 23
Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
Boylan, M. A., Pincetic, A., Romano, G. J., Tatton, N. A., Kenkare-Mitra, S., & Rosenthal, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115946 · Cited by 19
“However, the mechanisms by which neuronal and microglial PGRN directly contribute to AD pathology continue to be elucidated [167]; Table 1 provides an overview of the current state of the literature examining the effects of PGRN knockout and PGRN overexpression on neurons, microglia, and astrocytes…”
BackgroundProgranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes
Murakoshi, M., Gohda, T., Sakuma, H., Shibata, T., Adachi, E., Kishida, C., Ichikawa, S., Koshida, T., Kamei, N., & Suzuki, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.849457 · Cited by 21
Torso, M., Ridgway, G. R., Hardingham, I., Schwarz, A. J., & Chance, S. A. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.59 · Cited by 19
Wang, S., Weyer, M.-P., Hummel, R., Wilken‐Schmitz, A., Tegeder, I., & Schäfer, M. K. E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03249-7 · Cited by 18
“Several studies have reported the upregulation of PGRN in microglia after brain insult in humans and in animal models [1, 53, 54], and single-nucleus sequencing revealed that PGRN deficiency promotes a disease-associated state of microglia correlated with neurodegeneration in mice [55].”
BackgroundLan, J., Hu, Y., Wang, X., Zheng, W., Liao, A., Wang, S., Li, Y., Wang, Y., Yang, F., & Chen, D. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108689 · Cited by 17
Peroxisomal defects in microglial cells induce a disease-associated microglial signature
Raas, Q., Tawbeh, A., Tahri-Joutey, M., Gondcaille, C., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Leoni, V., Bellanger, E., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1170313 · Cited by 16
Kuo, Y., & Rajesh, R. (2020) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2020.09.012 · Cited by 15
Takahashi, K., Nakamura, S., Otsu, W., Shimazawa, M., & Hara, H. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02203-1 · Cited by 16
“by abnormal microglial activation [27].”
Associations of plasma neurofilament light chain and progranulin with frailty in older adults
Lu, W., Giudici, K. V., Guyonnet, S., Aggarwal, G., Nguyen, A. D., Morley, J. E., Vellas, B. J., Barreto, P. D. S., & MAPT/DSA Group (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17604 · Cited by 15
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Morley, J. E., Nguyen, A. D., Aggarwal, G., Parini, A., Li, Y., Bateman, R. J., Vellas, B. J., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac244 · Cited by 14
Dedert, C., Mishra, V., Aggarwal, G., Nguyen, A. D., & Xu, F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.874258 · Cited by 16
“Prior studies have shown that microglia express high levels of PGRN and may be important in neurodegeneration (Mendsaikhan et al., 2019; Choi et al., 2020), so we explored Frontiers in Cellular Neuroscience | www.frontiersin.org 4 July 2022 | Volume 16 | Article 874258 FIGURE 1 | Neuronal viability…”
BackgroundInfluentialThe Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target
Liu, G., Zhang, L., Fan, Y., & Ji, W. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206150 · Cited by 14
Rosenthal, Z. C., Fass, D. M., Payne, N. C., She, A., Patnaik, D., Hennig, K. M., Tesla, R., Werthmann, G. C., Guhl, C., Reis, S. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59110-7 · Cited by 13
Progranulin regulates the development and function of NKT2 cells through EZH2 and PLZF
Du, Z., Huang, L., Dai, X., Yang, D., Niu, L., Miller, H., Ruan, C., Li, H., Hu, L., Zhou, L., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00973-6 · Cited by 12
Yang, Y., Bagyinszky, E., & An, S. S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015461 · Cited by 11
“GRN played a significant role in immune-modulation neurodevelopment and synapse formation, and the reduced expression of GRN in the brain was suggested as a risk factor for AD [13,14].”
BackgroundVerwaerde, P., Estrella, C., Burlet, S., Barrier, M., Marotte, A.-A., & Clincke, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-220883 · Cited by 11
“PGRN is a growth factor highly expressed in central nervous system microglia and implicated in neurodegenerative disorders like frontotemporal dementia and certain forms of AD [6–8].”
PGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases
Shi, Y., Hou, W., Li, B., & Zhu, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08272-9 · Cited by 10
Early amyloid‐induced changes in microglia gene expression in male APP / PS1 mice
Oshima, T., Kater, M. S. J., Huffels, C. F. M., Wesseling, E. M., Middeldorp, J., Hol, E. M., Verheijen, M. H. G., Smit, A. B., Boddeke, E., & Eggen, B. J. L. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25295 · Cited by 9
“In human AD cases and AD model mice, increased expression of PGRN was observed in microglia (Mendsaikhan et al., 2019).”
BackgroundLiao, A., Zheng, W., Wang, S., Wang, N., Li, Y., Chen, D., & Wang, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70015 · Cited by 8
“Some research indicates an increase in PGRN levels following microglia activation, 50 which is not consistent with our observations.”
Extracellular Cleavage of Microglia-Derived Progranulin Promotes Diet-Induced Obesity
Park, C. B., Lee, C. H., Cho, K. W., Shin, S., Jang, W. H., Byeon, J., Oh, Y. R., Kim, S. J., Park, J. W., Kang, G. M., et al. (2024) · Diabetes · doi:10.2337/db24-0097 · Cited by 8
Meiman, E. J., Kick, G. R., Jensen, C. A., Coates, J. R., & Katz, M. L. (2022) · Developmental Neurobiology · doi:10.1002/dneu.22878 · Cited by 7
“…2020; Lynch, 2020; Stephenson et al., 2018; Wright-Jin & Gutmann, 2019), including NCL disorders (Bible et al., 2004; Groh et al., 2013, 2016; Katz et al., 2020; Kay & Palmer, 2013; Macauley et al., 2009; Mendsaikhan et al., 2019; Oswald et al., 2005; Pontikis et al., 2004; Xiong & Kielian, 2013).”
GRN Missense Variants and Familial Alzheimer’s Disease: Two Case Reports
Ingannato, A., Bessi, V., Chiari, A., Salvatori, D., Bagnoli, S., Bedin, R., Ferrari, C., Sorbi, S., & Nacmias, B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230689 · Cited by 6
“Moreover, studies demonstrated features of GRN immunoreactivity in microgliaaroundsenileplaquesin GRN mutationcar-riers [13, 33].”
Progranulin and neuropathological features of Alzheimer’s disease: longitudinal study
Nabizadeh, F., Zafari, R., & Initiative, A. D. N. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02715-9 · Cited by 6
Milanowski, J., Nuszkiewicz, J., Lisewska, B., Lisewski, P., & Szewczyk‐Golec, K. (2024) · Metabolites · doi:10.3390/metabo14020106 · Cited by 5
“However, we did not detect any statistically significant differences in progranulin concentrations between the PD groups without and with dyskinesia [67–70].”
BackgroundNeuroinflammation revisited through the microglial lens
Socodato, R., & Relvas, J. B. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00284 · Cited by 5
Budda, B., Mitra, A., Park, L., Long, H., Kurnellas, M., Bien‐Ly, N., Estacio, W. F., Burgess, B., Chao, G., Schwabe, T., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01817-4 · Cited by 8
“Deficits in PGRN can therefore contribute to the pathophysiology of AD via multiple mechanisms, including the aggregation of misfolded proteins, lysosomal dysfunction, complement activation, neuroinflammation, and astrogliosis, as well as aberrant microglial activation [33, 79, 81].”
Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice
Zhao, X., Hasan, S., Liou, B., Lin, Y., Sun, Y., & Liu, C.-J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020629 · Cited by 5
Bagyinszky, E., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209960 · Cited by 4
Long, S., Liu, Z., & Wang, Y. (2024) · Neuroreport · doi:10.1097/wnr.0000000000002002 · Cited by 3
“Microglial PGRN has even been considered a ‘brake’ to suppress excessive microglial activation by facilitating phagocytosis and lysosomal trafficking in microglia [10].”
BackgroundclrDV: a differential variability test for RNA-Seq data based on the skew-normal distribution
Li, H., & Khang, T. F. (2023) · PeerJ · doi:10.7717/peerj.16126 · Cited by 2
Sleep Characteristics and Cerebrospinal Fluid Progranulin in Older Adults: The CABLE Study
Wang, M., Sun, F.-R., Bi, Y., Ma, Y., Yin, J., Shen, X., Wang, X., Tan, L., & Yu, J. (2021) · Neurotoxicity Research · doi:10.1007/s12640-020-00326-6 · Cited by 2
“Actually, the biotechnology company “NeuroDyn” has made PGRN therapeutics a central therapeutic development program (Mendsaikhan et al. 2019).”
BackgroundSong, S., Do, A. N., Wang, L., Heo, G., Kwon, J., Western, D., Yang, S. J., Timsina, J., Liu, M., Budde, J., et al. (2025) · medRxiv · doi:10.1101/2025.10.29.25339064 · Cited by 2
“GRN (progranulin) was reported as sex-specific in frontotemporal dementia, amyotrophic lateral sclerosis, AD, and PD 36,37 .”
Exploring the Prognostic Role of Neurofilaments and SEMA3A in Multiple Sclerosis Progression
Pavelek, Z., Souček, O., Krejsek, J., Součková, I., Popovičová, A., Matyáš, D., Sobíšek, L., & Novotný, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178750 · Cited by 1
“Recent evidence suggests progranulin could be involved in modulating the chronic inflammatory environment and influencing neuronal survival in neurodegenerative conditions, including progressive stages of MS [10,11].”
Zhang, J., Yang, N., Zou, P., & Zong, X. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03924-x · Cited by 2
“Progranulin maintains lysosomal acidification and deg-radative capacity during chronic phagocytic load [25].”
Yao, X., Qin, R., Cui, Z., He, D., Sun, X., Sun, Y., & He, X. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12783 · Cited by 1
Osuna, R., & Guadalupe, D. (2012) · Americanae (AECID Library) · Cited by 2
Vastrad, B. M., & Vastrad, C. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484749
Episodic Memory Loss: When Alzheimer’s Disease Is Not the Answer
García‐Roldán, E., Tsai, R. M., Berger, A. C., & Macías, E. F. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240014
“In the brain, PGRN is expressed in neurons and microglia, and chronic PGRN deficiency results in lysosomal dysfunction, which in turn leads to aberrant microglial activation, neuroinflammation, and TDP-43 proteinopathy, culminating in neurodegeneration [7–9].”
BackgroundSoni, N. (2023) · eScholarship (California Digital Library)
Hisaki, H., Susa, T., Okudaira, N., Akimoto, M., Iizuka, M., Matsuda, J., Uchida, S., Okinaga, H., Okazaki, T., & Tamamori-Adachi, M. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102388 · Cited by 1
“Mendsaikhan et al. reported that PGRN immunoreactive structures in microglia are larger than those of neurons and do not localize in glial fibrillary acidic protein-positive astrocytes [14,45].”
Sajan, M. P., Aggarwal, G., Hwang, J. J., Smith, D. M., Cooper, D. R., Duncan, M. A., HANSEN, B. C., Nguyen, A. D., & Farese, R. V. (2026) · iScience · doi:10.1016/j.isci.2026.115720 · Cited by 1
Single-cell multiomics reveals microglia–neuron granulin signaling associated with brain agingPreprint
Han, S.-E., Kim, H., Song, J., Song, D., Cho, S., Kim, C., Kim, E., & Hwang, B. (2026) · Research Square · doi:10.21203/rs.3.rs-9134976/v1
Poniatowski, Ł. A., Eske-Pogodda, K., Siwińska, A., Olczak, M., Meinck, K., & Fritsch, M. J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156129
“Experimental and translational studies indicate that PGRN exerts neurotrophic and immunomodulatory effects, supports lysosomal function, influences microglial activation states, and may mitigate neurodegenerative damage [32,33].”
Yan, X., Zhang, L., Li, J., & Song, J. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01819-2
Pehlivan, Z. N., Zıkşahna, K., Adıyıl, R., & Ihlamur, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01993-8 · Cited by 1
Metadata
- Authors
- Mendsaikhan, A., Tooyama, I., & Walker, D. G.
- Affiliations
- Shiga University of Medical Science (JP)
- Corresponding author
- Mendsaikhan, Anarmaa
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-03-11
- Volume
- 8
- Issue
- 3
- Pages
- 230
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6468562
- OpenAlex
- W2920995467
- Cited by
- 72
- References
- 159
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 12 · 2020: 6 · 2019: 3
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (26290022)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- progranulin, microglia, Alzheimer's disease, neurodegenerative diseases, frontotemporal lobar degeneration, neuronal ceroid lipofuscinosis, lysosomal dysfunction, neuroinflammation, anti-inflammatory activity, neurotrophic factors
- MeSH terms
- Progranulins, Alzheimer Disease, Animals, Disease Models, Animal, Humans, Lysosomes, Microglia, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.